Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$2.85 USD
-0.02 (-0.70%)
Updated Aug 28, 2025 04:00 PM ET
After-Market: $2.85 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BDTX 2.85 -0.02(-0.70%)
Will BDTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDTX
Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know
Other News for BDTX
BDTX forms NR7 on August 27
BDTX rises 1.05% on August 26, leaving the technical picture intact
Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash
BDTX forms Stochastic Reached Overbought on August 25
Is BDTX building bullish momentum? MACD Bullish Centerline Cross shows up after surging 7.75%